INS and type 1 diabetes mellitus: In line with the promising anti-CD3 preventive T1D trial in children, PTM relevant autoantibody analysis (either anti-oxPTM-insulin and anti-PDIA1/P4Hb antibodies) may help establish the optimal time for therapeutic immune modulation of high-risk T1D individuals.